Cardio Diagnostics Holdings (NASDAQ: CDIO) is addressing a critical gap in coronary heart disease (CHD) detection with molecular precision tools that go beyond conventional risk assessment. The company reports that approximately 50% of individuals with CHD do not present with traditional risk factors, and conventional risk calculators have an average sensitivity of just 39%. This means many people who appear healthy may still develop CHD and suffer preventable cardiac events like heart attacks.
For decades, cardiovascular risk assessment has relied on a checklist of factors such as cholesterol levels, blood pressure, smoking history, diabetes status, family history, and weight. While these factors are useful, they were never designed to capture the full biological picture of how heart disease develops. CHD remains the leading cause of death in the United States, yet much of it is preventable if detected early.
Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics that examine how genes are expressed and regulated at the molecular level. These tests aim to identify individuals at risk even when traditional risk factors are absent. The company’s approach could transform early detection and prevention strategies for CHD.
The full terms of use and disclaimers are available on the InvestorBrandNetwork website. The latest news and updates relating to CDIO can be found in the company’s newsroom at https://ibn.fm/CDIO.
Forward-looking statements in this article involve risks and uncertainties, including those set forth under "Risk Factors" in the Company's filings with the SEC. Undue reliance should not be placed on these statements, and the Company undertakes no duty to update them unless required by law.
